Research About Impact of HPV Integration on the Prognosis of Women With Persistent HR-HPV Infection
Launched by FUJIAN MATERNITY AND CHILD HEALTH HOSPITAL · Mar 7, 2022
Trial Information
Current as of July 09, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying how the integration of the human papillomavirus (HPV) into cells affects the health outcomes of women who have a persistent high-risk HPV infection. Researchers are looking at 1,000 women who have had the same type of high-risk HPV for over 18 months or have certain cervical changes (CIN2 or higher). They will assess these women's HPV status and the diversity of their vaginal bacteria at different times over two years to see how these factors influence their health.
To participate, women must be non-pregnant and have a history of sexual activity. They should have had a persistent HPV infection for more than 18 months or have been diagnosed with CIN2 or higher. Women with previous cervical surgeries, recent infections, or those who have had HPV vaccinations are not eligible. Participants can expect to undergo regular health assessments and tests over two years, helping researchers understand how HPV integration impacts their condition. This information could be crucial in improving care for women with persistent HPV infections.
Gender
FEMALE
Eligibility criteria
- Inclusion Criteria:
- • Non pregnant people with sexual history;
- • Persistent infection of the same type of HR-HPV for more than 18 months or HR-HPV infection with CIN2 +;
- • No history of previous surgery at the cervical site.
- • Asexual life, no vaginal medication or flushing before 72 hours of sampling.
- Exclusion Criteria:
- • Within 8 weeks after pregnancy or postpartum.
- • Patients with history of genital tract tumor.
- • History of HPV vaccination.
- • Previous history of hysterectomy, cervical surgery, pelvic radiotherapy Historical.
- • In recent one month, she has received genital tract infection, HPV or other STDs treatment related to the infection of mycoplasma.
- • Use antibiotics or vaginal microecological improvement products in recent 1 month.
About Fujian Maternity And Child Health Hospital
Fujian Maternity and Child Health Hospital is a leading healthcare institution in China, dedicated to providing comprehensive maternal and pediatric care. With a strong emphasis on research and innovation, the hospital actively engages in clinical trials aimed at enhancing healthcare outcomes for mothers and children. Leveraging a team of experienced healthcare professionals and state-of-the-art facilities, the hospital fosters a collaborative environment for clinical research, contributing to advancements in reproductive health and pediatric medicine. Its commitment to quality care and scientific inquiry positions Fujian Maternity and Child Health Hospital as a pivotal player in the field of maternal and child health research.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Putian, Fujian, China
Longyan, Fujian, China
Zhangzhou, Fujian, China
Fuzhou, Fujian, China
Ningde, Fujian, China
Quanzhou, Fujian, China
Xiamen, Fujian, China
Ningde, Fujian, China
Longyan, , China
Nanjing, , China
Sanming, , China
Shenzhen, , China
Sanming, Fujian, China
Shenzhen, Guangdong, China
Patients applied
Trial Officials
Binhua Dong, MD
Study Chair
Fujian Maternity and Child Health Hospital
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials